Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Checkpoint-inhibitor
Melanoma
Serology
Side effect
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
05
2023
accepted:
07
07
2023
medline:
23
10
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1-5% of patients and can induce severe, permanent sequelae or even be fatal. In order to improve the diagnosis and treatment of neurological irAEs and to better understand their pathogenesis, we assessed whether previous neurotropic infections are associated with neurological irAEs. Neurotropic infections that might predispose to ICI-induced neurological irAEs were analyzed in 61 melanoma patients from 3 countries, the Netherlands, Australia and Germany, including 24 patients with neurotoxicity and 37 control patients. In total, 14 viral, 6 bacterial, and 1 protozoal infections previously reported to trigger neurological pathologies were assessed using routine serology testing. The Dutch and Australian cohorts (NL) included pre-treatment plasma samples of patients treated with neoadjuvant ICI therapy (OpACIN-neo and PRADO trials; NCT02977052). In the Dutch/Australian cohort a total of 11 patients with neurological irAEs were compared to 27 control patients (patients without neurological irAEs). The German cohort (LMU) consisted of serum samples of 13 patients with neurological irAE and 10 control patients without any documented irAE under ICI therapy. The association of neurological irAEs with 21 possible preceding infections was assessed by measuring specific antibodies against investigated agents. The seroprevalence of all the tested viral (cytomegalovirus, Epstein-Barr-Virus, varicella-zoster virus, measles, rubella, influenza A and B, human herpes virus 6 and 7, herpes simplex virus 1 and 2, parvovirus B19, hepatitis A and E and human T-lymphotropic virus type 1 and 2), bacterial (Borrelia burgdorferi sensu lato, Campylobacter jejuni, Mycoplasma pneumoniae, Coxiella burnetti, Helicobacter pylori, Yersinia enterocolitica and Y. pseudotuberculosis) and protozoal (Toxoplasma gondii) infections was similar for patients who developed neurological irAEs as compared to control patients. Thus, the analysis provided no evidence for an association of described agents tested for seroprevalence with ICI induced neurotoxicity. Previous viral, bacterial and protozoal neurotropic infections appear not to be associated with the development of neurological irAEs in melanoma patients who underwent therapy with ICI across 3 countries. Further efforts are needed to unravel the factors underlying neurological irAEs in order to identify risk factors for these toxicities, especially with the increasing use of ICI in earlier stage disease.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1-5% of patients and can induce severe, permanent sequelae or even be fatal. In order to improve the diagnosis and treatment of neurological irAEs and to better understand their pathogenesis, we assessed whether previous neurotropic infections are associated with neurological irAEs.
METHODS
METHODS
Neurotropic infections that might predispose to ICI-induced neurological irAEs were analyzed in 61 melanoma patients from 3 countries, the Netherlands, Australia and Germany, including 24 patients with neurotoxicity and 37 control patients. In total, 14 viral, 6 bacterial, and 1 protozoal infections previously reported to trigger neurological pathologies were assessed using routine serology testing. The Dutch and Australian cohorts (NL) included pre-treatment plasma samples of patients treated with neoadjuvant ICI therapy (OpACIN-neo and PRADO trials; NCT02977052). In the Dutch/Australian cohort a total of 11 patients with neurological irAEs were compared to 27 control patients (patients without neurological irAEs). The German cohort (LMU) consisted of serum samples of 13 patients with neurological irAE and 10 control patients without any documented irAE under ICI therapy.
RESULTS
RESULTS
The association of neurological irAEs with 21 possible preceding infections was assessed by measuring specific antibodies against investigated agents. The seroprevalence of all the tested viral (cytomegalovirus, Epstein-Barr-Virus, varicella-zoster virus, measles, rubella, influenza A and B, human herpes virus 6 and 7, herpes simplex virus 1 and 2, parvovirus B19, hepatitis A and E and human T-lymphotropic virus type 1 and 2), bacterial (Borrelia burgdorferi sensu lato, Campylobacter jejuni, Mycoplasma pneumoniae, Coxiella burnetti, Helicobacter pylori, Yersinia enterocolitica and Y. pseudotuberculosis) and protozoal (Toxoplasma gondii) infections was similar for patients who developed neurological irAEs as compared to control patients. Thus, the analysis provided no evidence for an association of described agents tested for seroprevalence with ICI induced neurotoxicity.
CONCLUSION
CONCLUSIONS
Previous viral, bacterial and protozoal neurotropic infections appear not to be associated with the development of neurological irAEs in melanoma patients who underwent therapy with ICI across 3 countries. Further efforts are needed to unravel the factors underlying neurological irAEs in order to identify risk factors for these toxicities, especially with the increasing use of ICI in earlier stage disease.
Identifiants
pubmed: 37606856
doi: 10.1007/s00262-023-03498-0
pii: 10.1007/s00262-023-03498-0
pmc: PMC10576679
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3475-3489Informations de copyright
© 2023. The Author(s).
Références
Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492. https://doi.org/10.1016/s1470-2045(18)30700-9 . ((in eng))
doi: 10.1016/s1470-2045(18)30700-9
pubmed: 30361170
Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L (2019) Checkpoint inhibitors. Dtsch Arztebl Int 116(8):119–126. https://doi.org/10.3238/arztebl.2019.0119 . ((in eng))
doi: 10.3238/arztebl.2019.0119
pubmed: 30940340
pmcid: 6454802
Spain L, Walls G, Julve M et al (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28(2):377–385. https://doi.org/10.1093/annonc/mdw558 . ((in eng))
doi: 10.1093/annonc/mdw558
pubmed: 28426103
Cuzzubbo S, Carpentier AF (2022) Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment. Curr Opin Neurol 35(6):814–822. https://doi.org/10.1097/wco.0000000000001113 . ((in eng))
doi: 10.1097/wco.0000000000001113
pubmed: 36226705
Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225
doi: 10.1016/j.ejca.2016.02.024
pubmed: 27084345
Voskens CJ, Goldinger SM, Loquai C et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1):e53745
doi: 10.1371/journal.pone.0053745
pubmed: 23341990
pmcid: 3544906
Knauss S, Ginesta Roque L, Hühnchen P, Heinzerling L, Böhmerle W, Endres M (2019) Neurological side effects of checkpoint inhibitors. Nervenarzt 90(2):138–147. https://doi.org/10.1007/s00115-018-0571-8
doi: 10.1007/s00115-018-0571-8
pubmed: 30073487
Moreira A, Loquai C, Pföhler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23. https://doi.org/10.1016/j.ejca.2018.09.033 . ((in eng))
doi: 10.1016/j.ejca.2018.09.033
pubmed: 30453170
Baldauf MC, Kapauer M, Joerger M et al (2021) Pembrolizumab-associated CD8(+) vasculitic mononeuritis multiplex in a patient with mesothelioma. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000993 . ((in eng))
doi: 10.1212/nxi.0000000000000993
pubmed: 33824184
pmcid: 8023979
Müller-Jensen L, Zierold S, Versluis JM et al (2022) Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer 175:224–235. https://doi.org/10.1016/j.ejca.2022.08.009 . ((in eng))
doi: 10.1016/j.ejca.2022.08.009
pubmed: 36155116
Voskens C, Cavallaro A, Erdmann M et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356–e357. https://doi.org/10.1200/jco.2011.41.4359 . ((in eng))
doi: 10.1200/jco.2011.41.4359
pubmed: 23045571
Schulz TU, Zierold S, Sachse MM et al (2022) Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients’ health-related quality of life. Eur J Cancer 176:88–99. https://doi.org/10.1016/j.ejca.2022.08.029 . ((in eng))
doi: 10.1016/j.ejca.2022.08.029
pubmed: 36198246
Nuñez NG, Berner F, Friebel E et al (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 4(2):113-129.e7. https://doi.org/10.1016/j.medj.2022.12.007 . ((in eng))
doi: 10.1016/j.medj.2022.12.007
Weiss J, Kirchberger MC, Heinzerling L (2020) Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease. Cancer Med 9(17):6132–6140. https://doi.org/10.1002/cam4.3191 . ((in eng))
doi: 10.1002/cam4.3191
pubmed: 32649807
pmcid: 7476834
Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A (2022) Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13:779691. https://doi.org/10.3389/fimmu.2022.779691 . ((in eng))
doi: 10.3389/fimmu.2022.779691
pubmed: 35558065
pmcid: 9086893
Muir CA, Clifton-Bligh RJ, Long GV et al (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106(9):e3704–e3713. https://doi.org/10.1210/clinem/dgab263 . ((in eng))
doi: 10.1210/clinem/dgab263
pubmed: 33878162
Rodríguez Y, Rojas M, Pacheco Y et al (2018) Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol 15(6):547–562. https://doi.org/10.1038/cmi.2017.142
doi: 10.1038/cmi.2017.142
pubmed: 29375121
pmcid: 6079071
Lee S, Levin MC (2008) Molecular mimicry in neurological disease: what is the evidence? Cell Mol Life Sci 65(7–8):1161–1175. https://doi.org/10.1007/s00018-007-7312-7 . ((in eng))
doi: 10.1007/s00018-007-7312-7
pubmed: 18193392
Rojas M, Restrepo-Jiménez P, Monsalve DM et al (2018) Molecular mimicry and autoimmunity. J Autoimmun 95:100–123. https://doi.org/10.1016/j.jaut.2018.10.012
doi: 10.1016/j.jaut.2018.10.012
pubmed: 30509385
Rozeman EA, Menzies AM, van Akkooi AC et al (2019) Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 20(7):948–960
doi: 10.1016/S1470-2045(19)30151-2
pubmed: 31160251
Rozeman E, Hoefsmit E, Reijers I et al (2021) Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27(2):256–263
doi: 10.1038/s41591-020-01211-7
pubmed: 33558721
Reijers IL, Menzies AM, van Akkooi AC et al (2022) Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 28:1178–1188
doi: 10.1038/s41591-022-01851-x
pubmed: 35661157
U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) Version 5.0. Available: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Clements DM, Crumley B, Chew GM et al (2021) Phenotypic and functional analyses guiding combination immune checkpoint immunotherapeutic strategies in HTLV-1 infection. Front Immunol 12:608890. https://doi.org/10.3389/fimmu.2021.608890 . ((in eng))
doi: 10.3389/fimmu.2021.608890
pubmed: 33767694
pmcid: 7985073
Shi Y, Zheng H, Wang M, Ding S (2022) Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter 27(2):e12878. https://doi.org/10.1111/hel.12878 . ((in eng))
doi: 10.1111/hel.12878
pubmed: 35112435
Zhu YC, Elsheikha HM, Wang JH et al (2021) Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002970 . ((in eng))
doi: 10.1136/jitc-2021-002970
pubmed: 34845005
pmcid: 8634011
Spagnolo F, Boutros A, Croce E et al (2021) Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: a systematic review. Eur J Clin Invest 51(7):e13604. https://doi.org/10.1111/eci.13604 . ((in eng))
doi: 10.1111/eci.13604
pubmed: 34021591
pmcid: 8365730
Lankes K, Hundorfean G, Harrer T et al (2016) Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 5(6):e1128611. https://doi.org/10.1080/2162402x.2015.1128611 . ((in eng))
doi: 10.1080/2162402x.2015.1128611
pubmed: 27471608
pmcid: 4938313
Lee KA, Shaw H, Bataille V, Nathan P (2020) Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-000577 . ((in eng))
doi: 10.1136/jitc-2020-000577
pubmed: 33335029
pmcid: 7745695
Bai Y, Xie T, Wang Z et al (2022) Efficacy and predictive biomarkers of immunotherapy in Epstein–Barr virus-associated gastric cancer. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-004080 . ((in eng))
doi: 10.1136/jitc-2021-004080
pubmed: 36600555
pmcid: 9730427
Malainou C, Herold S (2019) Influenza. Internist (Berl) 60(11):1127–1135. https://doi.org/10.1007/s00108-019-00670-6
doi: 10.1007/s00108-019-00670-6
pubmed: 31478058
Arshad Z, Alturkistani A, Brindley D, Lam C, Foley K, Meinert E (2019) Tools for the diagnosis of herpes simplex virus 1/2: systematic review of studies published between 2012 and 2018. JMIR Public Health Surveill 5(2):e14216. https://doi.org/10.2196/14216 . ((in eng))
doi: 10.2196/14216
pubmed: 31124465
pmcid: 6552407
Jain A, Jain P, Kumar A, Prakash S, Khan DN, Kant R (2018) Incidence and progression of Parvovirus B19 infection and molecular changes in circulating B19V strains in children with haematological malignancy: a follow up study. Infect Genet Evol 57:177–184. https://doi.org/10.1016/j.meegid.2017.11.021 . ((in eng))
doi: 10.1016/j.meegid.2017.11.021
pubmed: 29170063
Heinzerling L, Ascierto PA, Dummer R et al (2019) Adverse events 2.0-Let us get SERIOs: new reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer 112:29–31. https://doi.org/10.1016/j.ejca.2019.01.015 . ((in eng))
doi: 10.1016/j.ejca.2019.01.015
pubmed: 30903870
Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037 . ((in eng))
doi: 10.1016/j.jacc.2018.02.037
pubmed: 29567210
pmcid: 6196725
Bot I, Blank CU, Boogerd W, Brandsma D (2013) Neurological immune-related adverse events of ipilimumab. Pract Neurol 13(4):278–280. https://doi.org/10.1136/practneurol-2012-000447 . ((in eng))
doi: 10.1136/practneurol-2012-000447
pubmed: 23487828
Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389–399. https://doi.org/10.1038/s41574-021-00484-3 . ((in eng))
doi: 10.1038/s41574-021-00484-3
pubmed: 33875857
pmcid: 8769055
Husain B, Kirchberger MC, Erdmann M et al (2021) Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol 147(6):1623–1630. https://doi.org/10.1007/s00432-021-03550-5 . ((in eng))
doi: 10.1007/s00432-021-03550-5
pubmed: 33837821
pmcid: 8076116
Oster P, Vaillant L, Riva E et al (2022) Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut 71(3):457–466. https://doi.org/10.1136/gutjnl-2020-323392 . ((in eng))
doi: 10.1136/gutjnl-2020-323392
pubmed: 34253574
Obeidat A, Silangcruz K, Kozai L, Wien E, Fujiwara Y, Nishimura Y (2022) Clinical characteristics and outcomes of gastritis associated with immune checkpoint inhibitors: scoping review. J Immunother 45(8):363–369. https://doi.org/10.1097/cji.0000000000000435 . ((in eng))
doi: 10.1097/cji.0000000000000435
pubmed: 35972801
Brennan A, Hawley J, Dhand N et al (2020) Seroprevalence and risk factors for toxoplasma gondii infection in owned domestic cats in Australia. Vector Borne Zoonotic Dis 20(4):275–280. https://doi.org/10.1089/vbz.2019.2520 . ((in eng))
doi: 10.1089/vbz.2019.2520
pubmed: 31886739
Bogusz J, Augustynowicz E, Paradowska-Stankiewicz I (2021) Rubella in Poland in 2019. Przegl Epidemiol 75(4):588–596. https://doi.org/10.32394/pe.75.55 . ((in eng))
doi: 10.32394/pe.75.55
pubmed: 35543505
Hoefsmit EP, Rozeman EA, Haanen JB, Blank CU (2019) Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO open 4(4):e000472
doi: 10.1136/esmoopen-2018-000472
pubmed: 31423333
pmcid: 6677983
Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO III, Shah AA (2019) Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology 58(3):476–480
doi: 10.1093/rheumatology/key358
pubmed: 30508191
June CH, Warshauer JT, Bluestone JA (2017) Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 23(5):540–547
doi: 10.1038/nm.4321
pubmed: 28475571